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Abstract
Introduction: Pancreas adenocarcinoma (PDAC) remains a lethal malignancy with a
high‐mortality rate and poor long‐term survival. The management of PDAC has evolved
over the years to incorporate multidisciplinary care and numerous treatment modalities.
Body: We discuss the current standard of care for the management and treatment of
PDAC. We also discuss the value of managing PDAC patients with multidisciplinary
care, at high volume pancreas centers, with multimodality therapy, and with innovative
surgical techniques.
Conclusion: PDAC is an aggressive malignancy. Nuances in the management of the
disease can help to improve outcomes.
Keywords: pancreas adenocarcinoma, pancreas cancer, borderline resectable, neoad‐
juvant therapy, whipple, distal pancreatectomy, robotic surgery
1. Introduction
Pancreatic ductal adenocarcinoma (PDAC) is currently the 10th most commonly diagnosed
cancer in the United States and the third leading cause of cancer‐related mortality. It is expected
to become the second leading cause of cancer‐related death by 2030 [1, 2]. While most of the
other more common (lung, breast/prostate, and colon) causes of cancer‐related mortalities have
shown signs of down‐trending throughout the years, PDAC has shown an unfortunate upward
trend [3]. The increasing incidence and mortality is likely multifactorial, with increasing
environmental exposures, increase in survival age, or any other of the many stratifying risk
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factors. Regardless of the factors influencing the increasing risk of acquiring PDAC, the
aggressiveness of the disease itself should be a continued target in the attempt to control or
decrease the disease morbidity and mortality [3–5]. PDAC has an aggressive tumor biology
with a propensity for early metastasis. Less than 20% of patients with PDAC will present with
disease amenable to surgical and potentially curative therapy [1, 3].
The reason for the poor survival in PDAC patients is multifactorial. Tumor biology, lack of
screening and early diagnostic test, historically morbid surgical interventions, and systemic
therapies with limited efficacy are factors that have been shown to significantly affect the
outcomes of patients with PDAC. The combination of the aforementioned factors has led to
pessimism within the medical community about the efficacy of pancreatic disease manage‐
ment [6]. However, several advances have been made over the years; and with such a highly
lethal disease, any margin of progress can be a large gain. Some of these advances are related
to the improvement in coordination of care to overcome systemic barriers that limit the overall
efficacy in caring for the disease; other advances have been technical in nature; and finally,
several advances have been made in the approach of systemic therapies.
2. Multidisciplinary management team
One of the primary challenges of the modern healthcare system is the fractured nature in which
care is provided [7]. Patients with PDAC may be seen by a primary care doctor or gastroen‐
terologist but may never be seen by a medical or surgical oncologist, depending on disease
recognition and provider referral. In order to accomplish a more desirable outcome, a balance
must be reached between access to care and the quality of care provided. In a disease presenting
with many obstacles, providers having experience in managing PDAC and patients having
access to the most advanced therapies, including clinical trials, can make a significant
difference in outcomes. Research into these systemic healthcare factors has spurred the
production of various causal effect models; one model, in particular, demonstrates the effect
of the type of provider in charge of disease management and its impact on the patient receiving
expected treatment [7, 8].
Historically, the pessimistic outlook for patients with PDAC has generated skepticism
regarding the efficacy of therapy and resection. These attitudes adversely affect proven
beneficial disease management involving the utilization of surgical and medical interventions,
particularly evident in cases of early stage pancreatic cancer [7, 9, 10]. Bilimoria et al. were able
to demonstrate that despite modern improvements in survival after pancreatectomy, 51.7% of
Stage I patients did not undergo surgery for potentially resectable pancreatic cancer even after
accounting for patients who did not undergo surgery due to severe comorbidities, advanced
age, or patient refusal. Patients were less likely to undergo surgery if they were older, were
black, had lower annual incomes, had less education, or were on Medicare or Medicaid [6].
This difference in management exhibits a significant correlation with the racial and socioeco‐
nomic discrepancy. Similar discrepancies in care due to race and socioeconomic status have
been reported by several studies [11, 12]. Patients were more likely to receive surgery at
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academic institutions, high‐volume hospitals, and National Comprehensive Cancer Network
or National Cancer Institute (NCCN/NCI) centers. This was the first study to describe and
characterize such striking underuse of pancreatectomy while identifying factors predicting
underutilization [6, 7, 11].
While the initial referral is critically important, once a patient has been referred to a surgeon
or an oncologist, the provider's level of experience in managing PDAC is of equal, if not more,
significance. The early involvement of a pancreatic cancer specialist has been proven to exhibit
a most marked effect on early‐staged disease patients [7–9]. Physicians who care for PDAC
patients on a regular basis have several advantages over those who rarely treat the disease.
These advantages are evident when comparing perioperative and intraoperative statistics,
such as estimated blood loss, case duration, length of postoperative hospital stay, perioperative
death, and need for reoperations [13]. Evidence shows us that increased surgical or disease
management experience decreases disease morbidity [7, 13]. Improving morbidity, in an
already highly morbid disease, will help alter the pessimism surrounding PDAC through
recognition of some impactful management options.
It is known that surgery is the only curative therapy for PDAC [6]. It is also known that either
adjuvant or neoadjuvant therapy is the patient's best shot for a prolonged survival [7, 14, 15].
Recent evidence regarding oncological diseases has shown that the multidisciplinary approach
will have beneficial effects on disease management [7–10]. As such, the development of
multidisciplinary treatment teams and multimodal therapeutic interventions has become the
benchmarks of PDAC patient management. Most patients, regardless of stage, require multiple
subspecialty services including surgery, gastroenterology, medical and radiation oncology,
nutrition, and palliative care [7]. These teams allow for the development and collaboration of
specialty expertise, bringing a variety of perspectives to each PDAC case.
Although specific team composition may vary throughout center sites, studies continue to
illustrate the overall correlation of this model with improved quality of care. Studies assessing
the efficacy of this model have demonstrated decreased diagnosis‐to‐treatment time, increased
probability of receiving treatment, prolonged survival, increased involvement of multi‐
modality therapy, and increased enrollment and participation in clinical trials. One signifi‐
cantly impactful factor in this model is the decreased diagnosis‐to‐treatment time. Evidence
shows that approximately 80% of early Stage I/II diagnosed PDAC patients, not seen in
specialized, multidisciplinary centers, fail to receive a potentially curative surgery or life‐
prolonging treatment [8, 9]. Of early‐stage (Stage I/II) disease patients who did not receive
surgical resection, only 28% had a surgical referral. Of early‐stage patients who had received
surgical intervention, it was noted that referral to a pancreatic disease specialized center or
surgeon significantly impacted whether surgery was performed; 80% of early‐stage patients
seen in a specialized pancreatic disease clinic received surgery, whereas only 20% of compa‐
rable patients not seen in a specialized clinic received surgery [7, 16].
Another factor to consider multidisciplinary approach to caring for pancreatic cancer patients
is the greater accessibility and probability of the use of multimodal therapy. While studies
continue to show variance in the statistical significance of multimodal therapies, they remain
an important element in the development of more effective interventional therapies for such
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an aggressive cancer. Correspondingly, the inclusion of patients in clinical trials is another
benefit of multidisciplinary team centers. Studies have shown up to a two times higher
likelihood of patients participating in a clinical trial when seeing a multidisciplinary team. This
plays an important role in acquiring a greater understanding of the disease and the develop‐
ment of more effective therapies [7, 16].
Ultimately, the historical lack of multidisciplinary care is only one of multiple factors attributed
to the poor survivability curve seen in PDAC patients. However, in recent years, changes in
the management of PDAC have started to shift the curve toward showing improvement in the
acute care of patients as well as increasing the number of long‐term outcomes [17].
3. Defining the disease
The diagnosis of PDAC often remains a challenge. The utilization of various imaging modal‐
ities in the diagnosis and staging of PDAC continue to be utilized. Computed tomography
(CT), ultrasonography (US), magnetic resonance imaging (MRI), and endoscopic ultrasonog‐
raphy (EUS) are the routinely used modalities that are relatively accessible in hospitals and
specialized cancer centers. As the management of PDAC has advanced and become more
aggressive analogous to the nature of the disease, imaging modalities play an important role,
not only as a noninvasive option in the diagnostic phase of the disease but also in the deter‐
mination of disease burden, resectability, and the monitoring of treatment efficacy [18].
CT scanning is the accepted first line investigative modality in PDAC suspected patients. This
modality is usually preferred because it provides high‐resolution/quality images and relatively
wide availability, and its complete studies are relatively quicker than other high‐resolution
counterparts. CT scans are reported to provide 100% sensitivity and 72% specificity in
predicting the resectability of PDAC [19]. This modality also allows for the ability to use a
specific image‐attaining protocol for more thorough evaluation of the pancreas. This pancreas
protocol utilizes thin‐sectioned slices and captures images during certain postcontrast injection
time frames. Because PDAC is a hypovascular tumor, it is best detected in the late arterial phase
at 35–40 s postcontrast injection, when the normal pancreatic parenchymal tissue is most
optimally enhanced while the hypovascular tumor is not. At 70‐s postcontrast injection, the
portal venous system is optimally enhanced, which can prove helpful in assessing any extent
of venous involvement and identifying possible liver metastases. These two phases are
typically obtained during a pancreatic protocol CT. Of note, when there is a concern for
pancreatic islet cell (endocrine) tumor exists, an earlier (20–25‐s postcontrast injection), arterial
phase scan is usually most beneficial, since these tumors are often hypervascular. Some of these
endocrine tumors can be visualized in the portal venous phase as well, and thus dual phases
of arterial and portal venous scanning are usually done for suspected pancreatic endocrine
tumors. The pancreatic protocol CT scan produces images with PDAC classically appearing
as a hypodense lesion relative to the pancreatic parenchyma [19, 20]. On an approximate, 10%
of cases where PDAC lesions are isodense on imaging, distinguishing the tumor can be more
difficult. Other signs can be present on CT imaging that increase detection of a pancreatic mass.
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Lesions present in the pancreatic head can produce a secondary finding of “double duct” sign,
which is the presence of simultaneous dilation of the common bile and main pancreatic ducts.
This is due to the tumor in the head portion of the pancreas compressing the ducts causing
obstruction and fluid build‐up that result in dilation of both ducts. Tumor in the body or tail
of the pancreas can result in stenosis and obstruction of the main pancreatic duct, resulting in
an upstream dilation of the main pancreatic duct. These signs can be beneficial in distinguish‐
ing a more isodense lesion or in the confirmation of a smaller, hypodense PDAC lesion.
However, this modality can be limited in its ability to differentiate an isodense lesion and to
show possible metastatic disease when denoted by small lesions in certain areas such as the
peritoneum or liver [18, 20, 21].
One of the most sensitive and high‐quality image producing modalities to date is the MRI. The
MRI modality in comparison to CT scans provides greater soft tissue quality. This allows for
superiority in imaging of smaller tumors and fatty infiltration of the pancreatic parenchyma,
and in distinguishing lesions that would show as isodense lesion on CT scan. The most effective
MRI‐weighted imaging sequence for assessing the pancreas is the T1‐weighted, fat suppressed
sequence. In this sequence, PDAC usually appears hypointense [18]. Other sequences (T2‐
weighted, DWI, and GRE) have been shown to be relatively inconsistent in the PDAC intensity
seen on imaging; however, they are still useful in assisting thorough evaluation of the pancre‐
atic tissue. Another advantage of the MRI is the ability to perform a more in‐depth examination
of the pancreatic ducts utilizing magnetic resonance cholangiopancreatography (MRCP). This
technique allows for inspection of the ductal systems and ability to discern small ductal
narrowing secondary to a small lesion or to detect confounding etiologies to ductal dilation
such as a stone obstructing either the common bile or main pancreatic duct. MRCP, in con‐
junction with the MRI, can result in more efficacious detection in early stage pancreatic disease
by allowing more detailed study of the pancreatic parenchyma and ductal system. Limitations
of this modality in the diagnosis and interventional benefits in PDAC disease include
significant time for study completion, fairly high cost, easy susceptibility to artifact and
difficult accessibility in areas with limited resources [18, 21].
Ultrasonography (US) is a most likely and readily available modality than all other applicable
modalities in visualizing the pancreas. US can also be done very quickly with low cost and
increased portability. However, US scan of the pancreas is fairly low in quality, requires specific
preimaging preparation for the patient, and requires trained and experienced people for the
operation to be most effectively utilized. A minimum 6‐h fast is required to better visualize the
pancreas; this fast preparation improves visualization by limiting bowel gas and ensuring an
empty stomach. The scan protocol evaluates different sectional cuts (transverse, oblique, and
sagittal) along the pancreatic duct in the search for signs of obstruction or stenosis. This can
often visualize the pathognomonic observation of double duct sign in PDAC of the pancreatic
head. The PDAC lesion is often evident as a hypoechoic lesion on imaging. However, diag‐
nostic utility of US is highly dependent upon the operator's training and experience, the burden
or progression of disease, and the habitus of a patient [18, 21].
Endoscopic ultrasound (EUS) has been considered as a modality producing highly accurate
detection of small (greater than 3 cm) lesions. This modality provides visualization of the
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pancreatic tissue and parenchyma from the stomach or duodenum. It allows for higher quality
images to be obtained in comparison to standard US. EUS also has the benefit of being able to
obtain specimens via fine needle aspiration. On its own, EUS is not highly effective in
differentiating a chronic pancreatic disease such as chronic pancreatitis and pancreatic cancer,
with evidence showing the accuracy at 76% for detecting cancer and 46% for detecting a local
inflammation, whereas the combination of EUS and fine needle aspiration has shown to
increase the detection percentage of pancreatic cancer to 90% and above [18]. Limitations of
this modality include the necessity of conjoined procedures, including a more invasive, albeit
minimally, technique. Fine need aspiration is also not a widely and readily available resource
amongst all hospital and care centers.
One of the most important components of a multidisciplinary team is that the presenting state
of the disease is agreed upon, and a treatment plan is constructed in accordance with national
guidelines for care while also taking into account distinctive patient factors. The expertise of
the multidisciplinary team and standardized national definitions regarding disease staging
are associating factors best utilized concurrently in determining disease burden and the initial
steps in optimizing patient management. Although pathologic staging criteria for PDAC have
long been established through the American Joint Commission on Cancer (AJCC), clinical
staging criteria has not been as well defined. For an extensive period of time, common language
was lacking for defining the degree of tumor involvement with surrounding vasculature and
the subsequent classification of whether or not it is safely resectable. From a surgical perspec‐
tive, the determination for surgical intervention is based on the tumor's determined resecta‐
bility. By classifying patient tumors as resectable, borderline resectable, locally advanced, and
metastatic, the care team is better able to standardize treatment regimens for patients. Fur‐
thermore, more defined classifications allow for greater adherence to national guidelines [20,
22].
Although several definitions of resectability have emerged over the years, the most widely
accepted classification, which has also subsequently been incorporated in the National
Comprehensive Cancer Network (NCCN) criteria, was defined by Callery et al. [22]. They
constructed a consensus criterion based on radiographic CT findings in the preoperative
staging phase. Resectable tumors are those that (1) had demonstrated no distant metastases;
(2) had shown no radiographic evidence of superior mesenteric vein (SMV) and portal vein
abutment, distortion, tumor thrombus, or venous encasement; and (3) had shown clear fat
planes around the celiac axis, hepatic artery, and superior mesenteric artery. Borderline
resectable tumors are defined as those that (1) had shown no distant metastases; (2) demon‐
strated either some venous involvement of SMV/portal vein (a) with tumor abutment with or
without (i) impingement and narrowing of the lumen, (ii) encasement of the SMV/portal vein
without encasement of the nearby arteries, or (iii) short segment venous occlusion resulting
from either tumor thrombus or encasement, (b) but with suitable vessel proximal and distal
to the area of vessel involvement, which allows for safe resection and reconstruction; (3)
demonstrated some gastroduodenal artery encasement up to the hepatic artery with either
short segment encasement or direct abutment of the hepatic artery, without extension to the
celiac axis; and (4) demonstrated tumor abutment of the SMA not to exceed more than 180° of
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the circumference of the vessel wall. Locally advanced tumors were defined as those that fell
outside the definition of borderline resectable. Metastatic tumors were defined as those with
any evidence of metastatic disease [22].
Despite the relatively high accuracy in predicting unresectable disease, current imaging
modalities still lack indisputable certainty in predicting the degree of resectable disease. A
complimentary tool for increasing sensitivity in assessing a tumor's resectability and stage is
diagnostic laparoscopy. Per guidelines, for apparent resectable disease, utilization of laparo‐
scopy should be used with clinical predictors that optimize yield including pancreatic head
tumors greater than 3 cm, tumors of the pancreas body and tail, ambiguous findings on CT
scan, or high CA 19‐9 levels (>100 U/mL). In addition, locally advanced and unresectable
pancreatic cancer, without radiographic evidence of distant metastasis, should also be further
evaluated with laparoscopy in order to rule out subclinical metastatic disease so that the care
team's therapeutic management can be optimized [20, 22].
4. High‐volume centers
The outside referral to pancreatic cancer specialist, hospital, and institutional volume of
patients treated for pancreas cancer matters as well. The volume of patients treated and cases
seen directly correlate with the experience gained by the providers in the management care
team [13, 23]. The pancreaticoduodenectomy (PD) was classically a very morbid operation
with mortality after PD nearing 25% in the 1960s [6, 17]. The morbidity associated with the
operation was multifactorial. However, the factor most attributable to the morbidity is the risk
of pancreatic fistula development. Often unrecognized, and thus untreated, a pancreatic fistula
is the development of an abnormal communication between the pancreas and other organs
secondary to the leakage of pancreatic secretions from damaged pancreatic ducts. This
communication can prove highly detrimental to the involved organs. A pancreatic fistula
substantially contributes to the most morbid complications seen with the operation such as
erosion of retroperitoneal vessels and hemorrhage, intra‐abdominal abscess, sepsis, multisys‐
tem organ failure, and death [24]. Over the years, PD morbidity and mortality have improved
significantly, with mortality dropping to less than 3% in some high‐volume centers. The
involvement of high‐volume pancreatic surgical centers has greatly contributed to this decline.
Multiple studies have demonstrated a relationship between hospital surgical volume and
outcomes for pancreatectomy [24, 25]. Specifically illustrating that as hospital volume for
pancreatic surgery increases, perioperative mortality, postoperative complications, length of
stay, and overall cost decreases, and long‐term survival improves [6]. In 2011, a 10‐year
observational study (1999–2008) examined the relationship between cancer center volume and
particular cancer operations. PD was compared to several other cancer and high‐risk opera‐
tions including esophagectomy, lung resection, cystectomy, AAA repair, and carotid endar‐
tectomy, among others. The study found an increase in the median number of cancer and high‐
risk operations performed at hospitals. Pancreatic cancer surgery exhibited the greatest
observed median increase, with an approximate 200% national increase in the median number
of patients receiving pancreatic cancer surgery at each hospital, an increase of 5 patients per
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center to 16 per center. This figure is most notably influenced by the 56% national increase in
patients seen for pancreatic disease, and the 25% national decrease in the number of hospitals
performing the PD procedure, which does not detract from the fact that more pancreatic cancer
patients are being seen and more PD procedures are being done. The most encouraging finding
is that with this increase in PDAC patients seen and PD cases performed, there has been an
almost 20% decrease in the postpancreatectomy mortality (death prior to hospital discharge
or within 30 days after surgery). These findings denote a strong correlation observed between
the operative risk incurred and the hospital's relevant surgical case volume [25–27]. While some
high‐risk operations examined in the study showed minimal volume‐outcome relationship,
there was substantial evidence that the volume‐outcome relationship for PD is particularly
strong. It has also been suggested that differences in surgical technique, such as margin
involvement with resection, might be influential on the volume‐based differences seen in PD
mortality and morbidity. Resected margins showing cancerous involvement (margin‐positive)
are a poor prognostic factor after PD. The study found that patients undergoing PD at low‐
volume pancreatic cancer centers are more likely to have margin‐positive resections, either
macroscopic (R2), microscopic (R1), or both [26, 27]. These findings support the concept of
improved morbidity and mortality of PD at high‐volume centers and emphasize the impor‐
tance of PDAC patient referral to specialized, high‐volume centers.
5. Improvement in surgical care of the patient
Over the last 20 years, significant advances in preoperative evaluation, surgical techniques,
and postoperative care have reduced the perioperative morbidity and mortality associated
with pancreatic surgery. Mortality after pancreaticoduodenectomy has dropped from 25% in
the 1960s to less than 3% in some high‐volume centers, with recent studies suggesting
postresection long‐term survival rates approaching 30%.While numerous studies and guide‐
lines establish pancreatectomy as the primary intervention for localized PDAC, pessimism
concerning pancreatic cancer disease is the likely cause of continued skepticism in the efficacy
of resection. In opposition to this belief, surgeon cumulative and yearly volume in the
treatment of pancreatic diseases has emerged as a surrogate marker for quality outcomes.
Surgical volume produces surgical experience, and, as Birk et al. illustrated, higher volume
pancreatic centers result in lower operative mortality [25]. While the number of pancreatic
cancer centers is declining, the increase in case number correlating with the decrease in
morbidity and mortality suggests that the market concentration of cases is providing the
opportunity to obtain more experience for the surgeons performing them [25]. There has been
documentation illustrating that personal surgical volume can affect patient outcome [23, 24].
This concept illustrates the importance of surgical proficiency as a contributing factor on
operative morbidity and mortality, despite the complexity or high‐risk nature of the operation.
High‐volume centers offer the opportunity for pancreatic specialized surgeons to become more
experienced with the cancer operations as well as more accustomed to varying surgical
expectations and complications, thus resulting in reduced operative mortality and improved
outcomes. Evidence has emphasized the correlation of operative experience and case load,
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surgical benchmarks and the pancreatic surgical learning curve [23–25]. One study looking at
approximately 2200 pancreatic surgeries performed during 1984–1991 showed a significant
correlation between a surgeon's number of cases done and the mortality rate. Low‐volume
surgeons (<10 resections) exhibited a 16% mortality rate in comparison to higher volume
surgeons (>40 resections), who exhibited a 5% mortality rate (Fisher, list paper). Fisher et al.
also showed this concept to be true. The author looked at the first 11‐year period of a particular
surgeon's pancreatic practice, examining 162 Whipple procedures performed, divided into two
categories of low‐volume era (0–11 cases/year) and high‐volume era (>22 cases/year). Patients
in the low‐volume era had a higher likelihood of exhibiting one or more complications when
compared to patients in the high‐volume era (58% low volume vs 46% high volume) (Fisher).
Training environment, in addition to case volume, is important in acquiring and strengthening
the proficiency desired for preferred pancreatic surgical outcomes [16, 23, 25]. Surgeons at
academic or more specialized centers appeared to significantly progress at a greater rate, likely
due to the substantial experience of the providers available to initially assist in training or
mentoring more inexperienced surgeons.
6. Improvements in perioperative care
The perioperative phases of the surgically treated pancreatic cancer patient have substantially
improved due to the establishment of multidisciplinary care teams, the advancement of
diagnostic and interventional techniques, and the continued progression of surgical experience
and proficiency. While much of this can be attributed to the development of extensive technical
modalities and abilities, proper and successful recovery is also an essential factor in improving
postsurgical patient outcomes. The enhanced recovery after surgery (ERAS) program is a
multimodal strategy that attempts to mitigate functional loss and morbidity, while improving
recovery and progression of functional capabilities in the perioperative setting. The pathways
included in the ERAS strategy include various preoperative and postoperative recommenda‐
tions that have significant effect on a patient's morbidity development and hospital course [28].
Significant preoperative strategies include preoperative counseling, preoperative smoking and
alcohol cessation, decision to use oral bowel preparation, and anticoagulation and antimicro‐
bial prophylaxis [28–32]. Preoperative counseling, including procedural expectations and
postoperative objectives, allows for the subduing of surgical anxiety and fear. This in turn
results in improved postsurgical course [28]. Preoperative smoking and alcohol cessation can
substantially improve a patient's outcome. At least 1 month of abstainence from smoking and
alcohol reduces the otherwise two‐ to threefold postoperative morbidity increase seen in these
patients. Also, this concept results in a considerable reduction in the pulmonary and wound
complications often present in this group [28, 29]. Oral bowel preparation is thought to reduce
complications of the surgery. However, evidence has shown that there is no clinical benefit to
performing mechanical bowel preparation. Data actually show that there is more of an
increased risk of dehydration or electrolyte imbalance, particularly in elderly patients [28].
Thus, it is strongly recommended that mechanical bowel preparation not be used as a preop‐
erative strategy. The malignancy of pancreatic disease in conjunction with the major surgical
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procedure of PD puts the patient at a substantially higher risk of acquiring a venous throm‐
boembolic event (VTE). The evidence strongly supports the beneficial use of a heparin,
preferably low‐molecular‐weight heparin due to its 1× daily administration, in preventing or
significantly reducing the risk of VTE. Standard prophylaxis involves administration 2–12 h
prior to surgery and continuation until patient has fully mobilized, with some evidence
suggesting benefit of continuation until 4 weeks after discharge. Mechanical preventative
measures should also be utilized in even higher risk patients. Preoperative antibiotics are
another highly recommended strategy for improving postoperative course and outcome of
patients. Usual antibiotic prophylaxis recommended for pancreatic surgery include either 2 g
(30 mg/kg peds) of Ancef (cefazolin, first‐line), clindamycin( 900 mg, 10 mg/kg peds)/vanco‐
mycin (15 mg/kg adult/ped) plus gentamicin (5 mg/kg, 2.5 mg/kg peds), or the addition of 400
mg (6 mg/kg peds) Diflucan (fluconazole) for patients at high risk of acquiring fungal infection
such as in cases where there is enteric drainage of the pancreas [30]. Evidence indicates that
antibiotic prophylaxis should be initiated 30–60 min prior to skin incision for optimal efficacy
with repeated doses intraoperatively, depending on half‐life of the utilized drug.
It is noteworthy that postoperative strategies are somewhat more extensive; however, strongly
recommended strategies include adequate pain control, glycemic control, early diet advance‐
ment, early mobilization, and early removal of anastomotic drains (after 72 h). Pain control in
the postoperative period is often highly important in patient cooperation with postoperative,
recovery goals. While specific evidence for superiority between epidural, patient controlled
analgesia, and other intravenous medications is less, proper pain control evidently results in
earlier progression through postoperative objectives such as early mobilization. Postoperative
morbidity and mortality are greatly influenced and increased by hyperglycemia and insulin
resistance. Intensive care unit postoperative patients have been documented to exhibit a lower
complication risk with a reduced hyperglycemic rate. Because abdominal surgery is associated
with increased levels of insulin resistance, a significant increase in baseline postoperative
morbidity risk occurs since the risk of hyperglycemia increases. Insulin administration is
important in keeping glucose under control; however, caution must be taken for the prevention
of hypoglycemia. While evidence indicating best glucose levels is controversial, basic hyper‐
glycemic prevention will is needed to improve outcomes despite the baseline level [28, 31].
Furthermore, optimizing nutrition, with early diet advancement, in the postoperative period
remains a strongly recommended strategy as well. The majority of patients will be able to
tolerate oral intake shortly after elective PD. Evidence has shown that early oral intake is safe.
Recent evidence has shown that early initiation of regular diet is reasonable and safe, and that
enteral tube feeds illustrate no additional or greater benefit. There is also no evidence of
improved benefit or safety of provider‐controlled diet advancement (e.g., sips of liquids
compared to regular diet), and a patient‐controlled advancement as tolerated [28]. Another
often recommended postoperative strategy is early and/or scheduled patient ambulation or
mobilization. Patients should begin mobilizing or trying to ambulate in the morning of
postoperative day 1. This strategy significantly reduces standard postoperative complications
resulting from patient inactivity such as atelectasis and VTE risk. This can be encouraged
through removal of barriers to ambulating or mobilizing such as a foley, and setting incre‐
mental patient activity goals on a daily basis, such as laps around the hospital floor, moving
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to a chair for a set period of time, among others. This has shown to reduce the rate of postop‐
erative complications as well as reduce hospital length of stay and improve recovery time [28,
32].
While the aforementioned concepts and strategies prove significant for the management of
acute surgical patients, the overall management strategy for a pancreatic cancer patient has
substantially changed. Historically, nasogastric decompression postpancreatectomy, particu‐
larly PD, was deemed necessary, not only to avoid tension on the gastrojejunostomy but also
due to the concern of delayed gastric emptying, which was the most common complication
after the procedure. However, it has been shown that foregoing nasogastric decompression
after pancreatectomy (both PD and DP) is safe and does not result in increased frequency or
severity of postoperative complications, including placement or replacement of a nasogastric
tube after surgery. It also has no effect on length of stay or advancement to regular or post‐
gastrectomy diet [33].This evidence aligns with ERAS program recommendations for pan‐
createctomy patients. Nasogastric decompression should thus be reserved exclusively for
selected patients, particularly approximately 10–25% [34] of patients who develop delayed
gastric emptying (DGE) after PD.
Another topic of broad and current interest has been the use of intraperitoneal drains after
pancreatectomy. Multiple high‐volume single‐institution studies have shown either no
difference or a decreased overall complication rate with elimination of routine drainage. This
is likely the result of the elimination of a portal of entry for bacteria and a potential source of
strain on the anastomosis, the latter particularly with the use of closed suction drains. However,
when routine elimination of drains was evaluated in a multicenter randomized controlled trial,
there was an increase in the number of patients that had at least one? Grade 2 complication
(drain 52% vs no drain 68%; p = 0.047) and a higher complication severity (p = 0.027). Not only
was there an increase in morbidity, but also there was a fourfold increase in mortality from 3
to 12% in patients undergoing PD without intraperitoneal drain placement. It is important to
emphasize that these results apply only to PD patients, but based on the evidence, abandon‐
ment of routine intraperitoneal drainage in this group of patients is not safe. More studies are
needed to address the safety of early removal of drains in PD in compliance with ERAS
protocols. As for DP, the safety of routine elimination of drains is currently being evaluated in
a multicenter randomized controlled trial (NCT01441492, clinicaltrials.gov).
Finally, there is a strong recommendation for early removal of perianastomotic drains, usually
within 72 h. The anastomotic drains are believed to reduce the consequential effects seen with
minor pancreatic leaks. Evidence showed that early removal of a drain in low‐risk pancreatic
fistula patients (drain fluid amylase <5000 U/L) was associated with a significantly reduced
rate of pancreatic fistula formation, abdominal complications and pulmonary complications.
There has also been increased scrutiny surrounding whether drain placement is even necessary
to begin with. While there is data supporting this strategy, there is also data showing other‐
wise [32]. Van Buren et al. studied this concept by looking at 137 PD patients in a randomized
prospective multicenter trial, 68 with drain placement and 69 without. From the Level 1 data
provided, it was shown that elimination of the intraperitoneal drain in PD cases resulted in a
significant increase in severity and frequency of postoperative complications. Furthermore,
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the study also illustrated a fourfold increase in mortality (3–12%) [35]. This raises skepticism
toward findings in the previous literature and supports advocating caution against eliminating
the use of drains altogether. However, per ERAS recommendations, early removal of the drain
is associated with fewer and reduced rate of complications [28, 35].
These strategies provide a unified protocol for perioperative management of the PD procedure
that could likely prove beneficial to centers through reducing postoperative complication rates,
time of recovery and hospital length of stay [28, 32]. Ultimately, it is the summation of these
factors that contribute to the improvement in the postoperative outcomes of pancreatic cancer
patients. While the aforementioned concepts and strategies prove significant for the manage‐
ment of the acute surgical patient, the overall management strategy for a pancreatic cancer
patient has substantially changed [23, 25, 28, 32].
7. Technical advances
Many of the advances that are discussed above are system‐based and involve the perioperative
period of patient care. These have had a tremendous impact on patient outcomes in the
treatment of PDAC. But of all the modalities involved, surgery remains the only treatment
with the potential for cure in patients with localized pancreatic cancer. Significant improve‐
ments in preoperative evaluation and postoperative care have reduced the perioperative
morbidity and mortality associated with pancreatectomy. As previously discussed, mortality
after PD has dropped significantly and there have also been improvements in long‐term
survival rates. In addition to these changes, surgical technique itself is progressing and
evolving.
In an evidence‐based systematic review, Wright and Zureikat identified four key elements that
have allowed minimally invasive pancreatic surgery to gain momentum: safety, oncologic
efficacy, cost, and reproducibility. Even though the evidence available is not the result of
randomized controlled trials but instead on case series matched with cohorts undergoing open
procedures, morbidity and mortality have been shown to be comparable between minimally
invasive (MI) and open techniques. This applies for both PD and DP and encompasses all
modalities of MI techniques: laparoscopy, robotic‐assisted surgery, and their institutional
variations.
The main concern with the adoption of MI techniques for the treatment of PDAC is undoubt‐
edly oncologic efficacy. A study by Kendrick et al. favored MI technique by demonstrating
fewer delays to initiation of adjuvant chemotherapy after laparoscopic PD with similar
oncologic survival when compared to that in open procedure. Another study using the
National Cancer Data Base demonstrated no difference in oncologic outcomes between
laparoscopic and open PD [36]. In the setting of DP cases, Lee and colleagues (reference below)
showed similar oncologic outcomes and high rates of R0 resection between open and laparo‐
scopic DP. The mean number of lymph nodes evaluated in the aforementioned series was
higher with open DP (15.4) when compared with the minimally invasive techniques (10.4 with
laparoscopy and 12 with robotic approach). However, there was no statistically significant
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difference in the number of positive lymph nodes evaluated. Although the retrospective design
of these studies introduces the possibility of selection bias in terms of patient selection, surgeon
preference/experience, and preoperative patient and oncologic characteristics, the available
evidence so far demonstrates that laparoscopic and robotic approaches to pancreatectomy do
not adversely affect oncologic outcomes and add benefits such as decreased EBL and LOS [37–
39]. However, it is important to note that the sources of most of the available literature are high‐
volume centers, which introduces a potential source of bias and reinforces the importance of
patient evaluation and treatment at high‐volume centers with multidisciplinary teams.
Cost is one of the limitations of MI pancreatectomy, particularly the robotic technique.
However, some authors have shown the robotic technique to be cost effective when the
reduction in length of stay is taken into consideration [40, 41]. Additionally, the robotic
technical skills are potentially easier to acquire when compared to laparoscopic technique. This
is secondary to the advantages provided by stereotactic vision, robotic simulators, and training
consoles. The learning curve defined as 80 cases for a reduction in operative time may shorten
with time since the operative steps and training techniques have recently become better defined
[42].
Another noteworthy technical advancement is the incorporation of vascular resection (VR)
with PD. Tseng et al. described five types of venous resection and reconstruction involving
the superior mesenteric vein (SMV), portal vein (PV), or superior mesenteric‐portal venous
(SMPV) confluence. These are tangential resection with saphenous vein patch (V1), segmental
resection with splenic vein ligation and primary anastomosis (V2) or with interposition graft
(V3), segmental resection without splenic vein ligation and primary anastomosis (V4) or with
interposition graft (V5). In their single institution series, Tseng and colleagues demonstrated
that properly selected patients with PDAC of the head of the pancreas undergoing VR had
a median survival of approximately two years. There was no statistical difference between
survival of patients undergoing standard PD and those undergoing PD and VR (p = 0.177)
[43].
Adequate patient selection for PD with VR has been possible by technological advances in
computer tomography and by a multidisciplinary approach involving surgeons and radiol‐
ogists. While several single center studies [44–46] have demonstrated PD with VR to be safe,
a retrospective cohort analysis of the National Surgical Quality Improvement Program
database demonstrated increased postoperative morbidity and mortality with the inclusion of
venous resection [47]. This difference can be attributed to publication bias since most of the
previously published single center studies have been from high‐volume centers. Based on this,
PD with VR in carefully selected patients at high‐volume institutions opens up the possibility
of survival comparable to that of patients undergoing standard PD, even in the setting of an
increased frequency of R1 resections in patients that require VR [43].
Not only has surgical technique evolved but also, operative standards of care have been
improved. It is known that lymph node metastasis is a poor prognostic factor for PDAC of the
pancreatic head. The retrieval of an adequate number of lymph nodes or total lymph nodes
examined (TNLE) is a measure of quality of care. Not only does it lead to optimal locoregional
control but also, it is of upmost importance for pathological staging. Current NCCN guidelines
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recommend that at least 11 lymph nodes are retrieved and examined. Gleisner and colleagues
showed an association between TNLE and overall survival, but the association was not uniform
through time at their institution. Standards of care improved. We have found that less than 12
lymph nodes are inadequate lymphadenectomy [48].
8. Therapeutics
The standard chemotherapy regimen for advanced pancreatic cancer has historically been
monotherapy with gemcitabine [49]. In patients with metastatic PDAC, gemcitabine with nab‐
paclitaxel improved median overall survival (8.5 vs 6.7 months, HR = 0.72, p < 0.001), one‐year
survival (35 vs 22%), two‐year survival (9 vs 4%), and improved objective response rate (23 vs
7%) when compared with gemcitabine alone [50]. The most common Grade 3 or higher toxicity
events were neutropenia, fatigue, and neuropathy.
Given that the majority of patients who undergo resection with curative intent relapse within
2 years [51], the CONKO‐001 trial set to evaluate the efficacy of gemcitabine as adjuvant therapy
administered as a dose of 1 g/m2 on day 1, 8, and 15 every 4 weeks for 6 months. After a median
follow‐up of 136 months, patients treated with gemcitabine had an increased median disease‐
free survival (13.4 vs 6.7 months, HR, 0.55 [95% CI, 0.44–0.69]; p < 0.001) and prolonged overall
survival (HR, 0.76 [95% CI, 0.61–0.95]; p = 0.01) versus those patients who were only observed
after resection. In 2010, a randomized controlled trial compared the use of fluorouracil plus
folinic acid versus gemcitabine as adjuvant chemotherapy. There was no difference in survival
between the two treatments [52]. Although alternative chemotherapy regimens have since
emerged, utilizing other agents as either monotherapy or in combination with gemcitabine,
few studies have demonstrated significantly improved results [24].
There has been increased interest in the use of neoadjuvant therapy for the treatment of
pancreatic adenocarcinoma given the potential for better treatment tolerance, improved
delivery to an undisturbed tumor bed, avoidance of delay in therapy, treatment of occult
micrometastatic disease, and the potential of down staging borderline/unresectable tumors.
In a meta‐analysis evaluating 14 Phase II trials involving gemcitabine and 5‐FU chemotherapy
regimens (either as monotherapy or combination therapy), there was no difference in local
recurrence between patients who were initially considered resectable prior to systemic
therapy and those who were not. Only 1.8% of patients had a complete tumor response, while
18.8% of all patients had partial tumor response based on RECIST criteria or criteria defined
by the authors of each respective study. Pathologic response was not reported. While there
was no difference in survival between the groups of patients deemed resectable pretreatment
and those determined to be unresectable, approximately one‐third of tumors initially
classified as borderline/unresectable were suitable for resection after neoadjuvant therapy
[53].
Despite the lack of Phase III trials addressing neoadjuvant therapy, it is important to emphasize
its role in selecting patients who will be good surgical candidates once restaged after comple‐
tion of treatment. It not only allows for better patient selection based on tumor biology, but
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also increases the possibility of R0 resection and patient completion of multimodal therapy. In
contrast to the findings described previously, a neoadjuvant approach using gemcitabine‐
based chemo radiation resulted in a median survival of 34 months for the patients who were
candidates for PD versus 7 months for those who did no undergo surgical resection. Addi‐
tionally, this study revealed that a gemcitabine‐based approach to neoadjuvant therapy is
superior to 5‐FU and paclitaxel‐based preoperative regimens in terms of better survival of
patients after PD [54].
The FOLFIRINOX regimen, combining 5‐flurouracil, leucovorin, irinotecan, and oxaliplatin,
was first implemented in the ACCORD‐11 trial conducted by the PRODIGE group. Among
342 patients with previously untreated metastatic PDA, this regimen resulted in an increase
in median overall survival from 6.8 months in the gemcitabine group to 11.1 months in the
FOLFIRINOX group (HR = 0.57, p < 0.001). However, the regimen resulted in increased Grade
3 or 4 adverse effects secondary to treatment, such as neutropenia, febrile neutropenia,
thrombocytopenia, diarrhea, and sensory neuropathy. The toxicity of the regimen thus raises
concern for its use in patients with more advanced age, poor ECOG status, or greater
comorbidities. For this group of patients, gemcitabine with nab‐paclitaxel may be a better
option due to its safer toxicity profile, although response to treatment is not as impressive as
that observed with FOLFIRINOX. The efficacy of FOLFIRINOX as first‐line therapy in the
metastatic setting has prompted the evaluation of its potential in the neoadjuvant setting for
patients with borderline or locally advanced disease. FOLFIRINOX followed by chemora‐
diation as neoadjuvant therapy has been shown to be safe in selected patients and has been
shown to result in R0 resections [55]. As FOLFIRINOX continues to become increasingly
incorporated into clinical practice, further study of patients who tolerate the regimen will
help determine predictive factors associated with improved response to this therapy [56–68].
9. Conclusion
Pancreas adenocarcinoma is an aggressive malignancy. Progression to a multidisciplinary
approach to diagnosis, treatment, and perioperative patient management can improve patient
outcomes. This can be achieved through the implementation of state‐of‐the‐art diagnostic
modalities, including imaging and endoscopic procedures, as well as the application of
enhanced recovery pathways that address every aspect of the treatment process from preop‐
erative patient optimization to postoperative rehabilitation. Advances in surgical technique,
particularly the use of laparoscopy and robotic‐assisted surgery, also provide benefits to
patients without compromising oncologic outcomes. Lastly, advancements in systemic
chemotherapy, although slower in progression, have shown some improvement in survival
when combined with surgical resection and offer a treatment alternative to patients with
advanced disease who are not surgical candidates.
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